Chronic aldosterone administration causes Nox2-mediated increases in reactive oxygen species production and endothelial dysfunction in the cerebral circulation

Journal of Hypertension

Volumn 32, Issue 9, 2014, Pages 1815-1821

  Chrissobolis, Sophocles ^a   Drummond, Grant R ^a   Faraci, Frank M ^b,c   Sobey, Christopher G ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF IOWA   (United States)

^c Iowa City Veterans Affairs Health Care System   (United States)

Author keywords

aging; cerebral artery; cerebrovascular disease; endothelium; Nox2

Indexed keywords

ACETYLCHOLINE; ALDOSTERONE; PHORBOL DIBUTYRATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; CYBB PROTEIN, MOUSE; L 012; LUMINOL; MEMBRANE PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ADULT; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BASILAR ARTERY; BLOOD PRESSURE; BRAIN CIRCULATION; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; KIDNEY MASS; MALE; MOUSE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; AGE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN ARTERY; CARDIOVASCULAR DISEASES; DEFICIENCY; DIAGNOSTIC USE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

AGE FACTORS; ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; ENDOTHELIUM, VASCULAR; LUMINOL; MALE; MEMBRANE GLYCOPROTEINS; MICE; NADPH OXIDASE; REACTIVE OXYGEN SPECIES; RISK FACTORS; SUPEROXIDES;

EID: 84906101692     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000259     Document Type: Article

References (50)

1. Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM. Aldosterone as a modulator of immunity: Implications in the organ damage. J Hypertens 2011; 29:1684-1692
2. Han F, Ozawa H, Matsuda KI, Lu H, De Kloet ER, Kawata M. Changes in the expression of corticotrophin-releasing hormone, mineralocorticoid receptor and glucocorticoid receptor mRNAs in the hypothalamic paraventricular nucleus induced by fornix transection and adrenalectomy. J Neuroendocrinol 2007; 19:229-238
3. Rigsby CS, Burch AE, Ogbi S, Pollock DM, Dorrance AM. Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1754-R1763
4. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol 2011; 300:H1566-H1582
5. Osmond JM, Rigsby CS, Dorrance AM. Is the mineralocorticoid receptor a potential target for stroke prevention?. Clin Sci (Lond) 2008; 114:37-47
6. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in japan: Comparative study with essential hypertension. The research committee of disorders of adrenal hormones in Japan. J Endocrinol Invest 1995; 18:370-373
7. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248
8. Park YM, Lim BH, Touyz RM, Park JB. Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt- induced hypertensive rat. J Korean Med Sci 2008; 23:1039-1045
9. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40:504-510
10. Xavier FE, Blanco-Rivero J, Avendano MS, Sastre E, Yela R, Velazquez K, et al. Aldosterone alters the participation of endothelial factors in noradrenaline vasoconstriction differently in resistance arteries from normotensive and hypertensive rats. Eur J Pharmacol 2011; 654:280-288
11. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012; 59:324-330
12. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004; 109:2213-2220
13. Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens 2009; 27:2192-2200
14. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13:189-197
15. Tasatargil A, Tekcan M, Celik-Ozenci C, Ece Gungor N, Dalkiran B. Aldosterone-induced endothelial dysfunction of rat aorta: Role of poly(ADP-ribose) activation. J Renin Angiotensin Aldosterone Syst 2009; 10:127-137
16. Xavier FE, Aras-Lopez R, Arroyo-Villa I, Campo LD, Salaices M, Rossoni LV, et al. Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane a2 and prostacyclin. Br J Pharmacol 2008; 154:1225-1235
17. Blanco-Rivero J, Cachofeiro V, Lahera V, Aras-Lopez R, Marquez-Rodas I, Salaices M, et al. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 2005; 46:107-112
18. De Silva TM, Broughton BR, Drummond GR, Sobey CG, Miller AA. Gender influences cerebral vascular responses to angiotensin II through Nox2-derived reactive oxygen species. Stroke 2009; 40:1091-1097
19. Miller AA, Drummond GR, De Silva TM, Mast AE, Hickey H, Williams JP, et al. NADPH oxidase activity is higher in cerebral versus systemic arteries of four animal species: Role of Nox2. Am J Physiol Heart Circ Physiol 2009; 296:H220-H225
20. Chrissobolis S, Miller AA, Drummond GR, Kemp-Harper BK, Sobey CG. Oxidative stress and endothelial dysfunction in cerebrovascular disease. Front Biosci 2011; 16:1733-1745
21. Chrissobolis S, Banfi B, Sobey CG, Faraci FM. Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. J Appl Physiol 2012; 113:184-191
22. Miller AA, De Silva TM, Judkins CP, Diep H, Drummond GR, Sobey CG. Augmented superoxide production by nox2-containing nadph oxidase causes cerebral artery dysfunction during hypercholesterolemia. Stroke 2010; 41:784-789
23. Gorelick PB. Risk factors for vascular dementia and alzheimer disease. Stroke 2004; 35:2620-2622
24. Krug AW, Allenhofer L, Monticone R, Spinetti G, Gekle M, Wang M, Lakatta EG. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-Activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 2010; 55:1476-1483
25. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J, et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 1995; 9:202-209
26. Channon KM, Qian H, Neplioueva V, Blazing MA, Olmez E, Shetty GA, et al. In vivo gene transfer of nitric oxide synthase enhances vasomotor function in carotid arteries from normal and cholesterol-fed rabbits. Circulation 1998; 98:1905-1911
27. Higueras J, Sarria B, Ortiz JL, Cortijo J, Maruenda A, Barbera M, Morcillo EJ. Halothane inhibits endothelium-dependent relaxation elicited by acetylcholine in human isolated pulmonary arteries. Eur J Pharmacol 1997; 326:175-181
28. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-Tolerance. J Clin Invest 1995; 95:187-194
29. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 2011; 31:1368-1376
30. Pena Silva RA, Chu Y, Miller JD, Mitchell IJ, Penninger JM, Faraci FM, Heistad DD. Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging. Stroke 2012; 43:3358-3363
31. Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimers disease with combined amyloid-beta and cerebrovascular pathology. PLoS One 2013; 8:e68612
32. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA. Role of nadph oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001; 88:947-953
33. Chrissobolis S, Faraci FM. The role of oxidative stress and nadph oxidase in cerebrovascular disease. Trends Mol Med 2008; 14:495-502
34. Faraci FM, Didion SP. Vascular protection: Superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004; 24:1367-1373
35. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011; 10:453-471
36. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol 2011; 300:H397-H407
37. Chrissobolis S, Faraci FM. Sex differences in protection against angiotensin II-induced endothelial dysfunction by manganese superoxide dismutase in the cerebral circulation. Hypertension 2010; 55:905-910
38. Chao CT, Wu VC, Kuo CC, Lin YH, Chang CC, Chueh SJ, et al. Diagnosis and management of primary aldosteronism: An updated review. Ann Med 2013; 45:375-383
39. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281
40. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345:1689-1697
41. Jia Z, Aoyagi T, Kohan DE, Yang T. mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol 2010; 299:F155-F166
42. Schreier B, Rabe S, Schneider B, Ruhs S, Grossmann C, Hauptmann S, et al. Aldosterone/NaCl-induced renal and cardiac fibrosis is modulated by TGF-( responsiveness of T cells. Hypertens Res 2011; 34:623-629
43. Miller AA, Drummond GR, Schmidt HHW, Sobey CG. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 2005; 97:1055-1062
44. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through Nox-2-derived radicals. Arterioscler Thromb Vasc Biol 2006; 26:826-832
45. Gupte SA, Kaminski PM, George S, Kouznestova L, Olson SC, Mathew R, et al. Peroxide generation by p47phox-src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction. Am J Physiol Heart Circ Physiol 2009; 296:H1048-H1057
46. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012; 18:1429-1433
47. Dinh QN, Arumugam TV, Young MJ, Drummond GR, Sobey CG, Chrissobolis S. Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke. Exp Transl Stroke Med 2012; 4:21
48. Dorrance AM, Rupp NC, Nogueira EF. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 2006; 47:590-595
49. Frieler RA, Meng H, Duan SZ, Berger S, Schutz G, He Y, et al. Myeloidspecific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 2011; 42:179-185
50. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, et al. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol 2007; 566:153-159.